Cytoreductive HIPEC-Combined Surgery in Treatment of Advanced Ovarian Cancer
Background. Ovarian cancer ranks 5th in the structure of female oncological mortality in the Russian Federation, with a first-year post-diagnosis rate of almost 35%. In 75% cases, ovarian cancer is diagnosed at stages III-IV. The disease usually represents as peritoneal carcinomatosis regarded as an advanced form that demands attention, which renders the issue highly relevant. We present a literature review and analysis of combined treatment outcomes in ovarian cancer patients hospitalised at the Kuvatov Republican Clinical Hospital within period 2020-2021.Materials and methods. The article reviews foreign and national scientific literature, as well as reports the case data on 18 patients diagnosed with ovarian cancer and treated at the Department of Oncology of the Kuvatov Republican Clinical Hospital within period 2020-2021.Results and discussion. A complete cytoreductive surgery was performed in 100% cases. In cohort I, mean operation time was 256 vs. 364 min, mean intraoperative blood loss - 1200 vs. 1050 mL, mean hospital stay - 14.6 vs. 18.7 bed-days. Postoperative complications were 16.7 vs. 50% in cohort I vs. II. A 30-day mortality rate was 0 vs. 16.6% in cohort I vs. II. The monitoring and enrolment of patients currently continues.Conclusion. A HIPEC procedure is not a radical measure and can only achieve a maximum efficacy if coupled with a complete cytoreduction. The treatment of stage III-IV ovarian cancer patients in a concurrent combined approach is promising and requires further in-depth research and a more robust statistics.